Page last updated: 2024-08-25

bexarotene and Dysmyelopoietic Syndromes

bexarotene has been researched along with Dysmyelopoietic Syndromes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arora, J; Cho, E; Espinoza-Delgado, I; Ferguson, A; Gore, SD; Greer, J; Jones, RJ; Kowalski, J; Matsui, WH; Norsworthy, KJ; Pratz, KW; Sakoian, S; Showel, M; Smith, BD; Sutherland, LA; Tsai, HL; Warlick, E	1

Trials

1 trial(s) available for bexarotene and Dysmyelopoietic Syndromes

Article	Year
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. Leukemia research, 2016, Volume: 49 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bexarotene; Female; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Pyridines; Recombinant Proteins; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; U937 Cells	2016

Article

Year

Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

Leukemia research, 2016, Volume: 49

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bexarotene; Female; Granulocyte-Macrophage Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Pyridines; Recombinant Proteins; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Treatment Outcome; U937 Cells

2016